BioDrugs

, Volume 26, Issue 2, pp 71–82

Rituximab

Current Status as Therapy for Malignant and Benign Hematologic Disorders
  • Nihal E. Abdulla
  • Mary J. Ninan
  • Avi B. Markowitz
Review Article

DOI: 10.2165/11599500-000000000-00000

Cite this article as:
Abdulla, N.E., Ninan, M.J. & Markowitz, A.B. BioDrugs (2012) 26: 71. doi:10.2165/11599500-000000000-00000

Abstract

Rituximab is a chimeric monoclonal antibody targeting the pan-B-cell antigen CD20 and was the first monoclonal antibody approved for clinical use in the treatment of cancer. Since its first approval by the FDA in 1997, investigators have continued to explore a variety of clinical conditions in which rituximab has proven effective with minimal toxicity. Rituximab, as monotherapy or in combination with chemotherapy, has been studied extensively in untreated and relapsed/refractory settings as both induction and maintenance therapy for the treatment of CD20-positive lymphomas and chronic lymphocytic leukemia, in addition to non-malignant hematologic disorders including autoimmune hemolytic anemia and immune thrombo-cytopenic purpura. Here we discuss the clinical development of rituximab with a review of the efficacy data from clinical trials and its current status in the practice of hematology and oncology.

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Nihal E. Abdulla
    • 1
  • Mary J. Ninan
    • 1
  • Avi B. Markowitz
    • 1
  1. 1.Division of Hematology/OncologyUniversity of Texas Medical Branch (UTMB)GalvestonUSA